Le Lézard
Classified in: Health
Subjects: PET, MRR

Veterinary Dermatology Drugs Market Set to Surge with Strong CAGR by 2024, Insights on Emerging Trends


DUBLIN, Feb. 7, 2024 /PRNewswire/ -- The "Veterinary Dermatology Drugs Global Market Report 2024" has been added to  ResearchAndMarkets.com's offering.

Research and Markets Logo

The global veterinary dermatology drugs market is experiencing a robust growth trajectory, according to a comprehensive new study. Industry analysis indicates a projected rise from $7.75 billion in 2023 to $8.67 billion in 2024, advancing at a compound annual growth rate (CAGR) of 11.9%. Underpinning this surge is an interplay of factors including heightened pet healthcare awareness and an uptick in veterinary spending.

Key Market Drivers

The market report delves into the principal forces propelling growth in this niche sector. The pervasiveness of dermatological disorders in animals, evolving patterns in pet care, and innovations in veterinary medication are pivotal elements fueling expansion. The uptick in pet ownership?a result of heightened responsibility towards animal well-being?has emerged as a primary catalyst in the market's progression.

Geographic Expansion and Future Outlook

With North America maintaining the largest regional share in 2023, the spotlight is now shifting to Asia-Pacific, forecasted to emerge as the fastest-growing region. By 2028, the veterinary dermatology drugs market is anticipated to escalate to $13.42 billion at a CAGR of 11.5%, buoyed by factors such as comprehensive pet insurance uptake and increasing pet healthcare literacy among consumers.

Emerging Trends in Veterinary Dermatology

Corporate Synergies and Expansion Efforts

Strategic partnerships and acquisitions constitute significant steps undertaken by market players to consolidate their position and diversify their portfolios. Recent industry activity demonstrates an unwavering commitment to fostering innovative solutions to pressing dermatological challenges in veterinary medicine.

Market Segmentation Insights

The study provides a granular examination of market segments based on the nature of veterinary dermatology drugs?antifungal, antibacterial, and antiparasitic. These segments cater to a wide array of indications in animals, from parasitic infections to allergic reactions, across multiple distribution channels including retail and online platforms.

Comprehensive Market Analysis

This report illuminates the integral components of the veterinary dermatology drugs market, furnishing a thorough analysis of current patterns and prospective future developments. Industry professionals, stakeholders, and strategists will find this an indispensable resource, offering direction for informed decision-making and strategic planning within the veterinary healthcare ecosystem.

The study affirms the dynamic nature of the veterinary dermatology drugs market, underlined by innovative treatments, strategic corporate maneuvers, and a robust growth trajectory, presenting a promising horizon for entities invested in animal welfare and veterinary healthcare.

Key Markets Covered:

Companies Profiled

For more information about this report visit https://www.researchandmarkets.com/r/nsfg2j

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo - https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets


These press releases may also interest you

at 07:10
bluebird bio, Inc. announced today that it will host a conference call to discuss first quarter 2024 results and business updates on May 9, at 8:00 a.m. ET. To participate in the conference call, please dial +1 (800) 715-9871 (U.S. and Canada) and...

at 07:05
Can-Fite BioPharma Ltd. , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced it received a Notice of Allowance from the European Patent Office for its...

at 07:05
Stoke Therapeutics, Inc. , a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the first quarter of 2024 and...

at 07:05
bluebird bio, Inc. announced today that it has completed the first commercial cell collection for LYFGENIA (lovotibeglogene autotemcel), a one-time gene therapy for the treatment of sickle cell disease in patients with a history of vaso-occlusive...

at 07:05
Xeris Biopharma Holdings, Inc. , a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into an exclusive...

at 07:01
Ginkgo Bioworks , which is building the leading platform for cell programming and biosecurity, today announced its participation in the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 7-11, in Baltimore, MD. Ginkgo will...



News published on and distributed by: